Price movement over the last 24 hours
Adaptive Biotechnologies Corp vs S&P Global Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while S&P Global Inc trades at $442.26 (market cap $131.26B). The key difference: S&P Global Inc is far larger — about 39.4× Adaptive Biotechnologies Corp's market cap, and S&P Global Inc pays a 0.87% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | SPGI | |
|---|---|---|
Market Cap | $3.33B | $131.26B |
Sector | Health | Financials |
52-Week High | $22.37 | $534.79 |
52-Week Low | $10.24 | $370.42 |
Enterprise Value | $3.19B | $143.23B |
Dividend Yield | — | 0.87% |
Trailing returns across standard periods
Latest headlines on both assets
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →